Century Therapeutics (IPSC) Cash from Investing Activities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Investing Activities data on file, last reported at -$112.6 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$112.6 million, down 503.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.0 million (down 151.74% YoY), and the FY2025 annual result was $107.5 million, up 126.4% from the prior year.
• Cash from Investing Activities declined to -$112.6 million in Q1 2026 per IPSC's latest filing, from $22.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $39.2 million in Q3 2024 and troughed at -$112.6 million in Q1 2026.
• A 5-year average of $5.3 million and a median of $18.6 million in 2023 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 829.55% in 2024 and fell as far as 585.57% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$4.3 million in 2022, then jumped by 535.36% to $18.6 million in 2023, then soared by 64.52% to $30.6 million in 2024, then dropped by 26.94% to $22.4 million in 2025, then sank by 603.62% to -$112.6 million in 2026.
• Business Quant data shows IPSC's Cash from Investing Activities at -$112.6 million in Q1 2026, $22.4 million in Q4 2025, and $24.7 million in Q3 2025.